Journal of Integrative Oncology

Beverly Hills Cancer Center, Cell Works Group, Inc., Personalized Cancer Medicine PLLC, Santa Monica, California 90401, USA

Publications

• Commentary   
  Drug Re-purposing to Defeat the Complex Adaptive Network of HPV-derived Cancer
  Author(s): Michael P. Castro, MD*
  
  Three decades of basic research have largely elucidated the oncogenic mechanisms of human papilloma virus (HPV). HPV protein E5 achieves a takedown of antigen presentation to evade immune evasion while also impairing the ubiquitin turnover of EGFR. HPV E6 and E7 causes turnover of key tumor suppressor genes, p53 and PTPN13, and Rb1 and PTPN14, respectively. The signaling pathway consequences and resulting transcriptional reorganization that results in malignant behavior is discussed regarding the complex, self-perpetuating network of HPV. The potential utility of network-targeting combination therapy by re-purposing rimantidine, withaferin A, and curcumin to rescue the tumor suppressor proteins and re-establish immune recognition is discussed as a strategy to achieve deactivation of the malignant network that leads to collapse of the disease and reversal of therapeutic resistance. Inv.. Read More»
  DOI: 10.37421/2329-6771.2024.15.506

  Abstract HTML PDF